Quarter 3 2019

Ticker	Phase	Drug	Notes	Data Results
BLRX	2b	BL-8040	Interim data 2h 2019
CAPR	2	HOPE-2	interim data early Q3
CARA	2	Oral KORSUVA	For treatment of pruritus in stage III. top-line data in 2H of 2019.
CARA	3	KORSUVA injection	For Chronic Kidney Disease-Associated Pruritus. Data expects 2H 2019.
CNCE	2	CTP-543	for treatment of moderate-to-severe alopecia areata.
DRRX	2a	DUR-928	for Psoriasis data second half of 2019.
GLYC	3	RESET	Patient enrollment completed in May 6.
ITCI	3	Lumateperone	for neuropsychiatric and neurodegenerative diseases. Study 401 and Study404	Data failed
NTRP	2	Bryostatin	Data anticipated in Q3	For Alzheimer's disease
SLGL	3	Epsolay	op-line results in papulopustular rosacea in mid-2019.
SUPN	3	P301+302 for SPN-80	Data anticipated in 2H 2019
SYBX	1b/2a	SYNB1618	For study in patients with PKU. data P1/2a in 3Q.
URGN	2b	UGN-102	Initial data from the OPTIMA II trial of UGN-102 is expected in 2H 2019

Quarter 2 2019

Ticker	Phase	Drug	Notes	Data Results
ACHN	2	ACH-4471	Interim data to be released in May 2019	reports positive interim data for ACHN-4471
ALBO	2	A4250	data in childen with Alagile syndrome and biliary astresia at EASL, April 12.	data update April 12.
ARDS	2	AR-105	data mid-2019
ASMB	2a	ABI-H0731	combination studies in HBV patients expected Q2.	Data update April 13.
ATRA	3	ATA 129 tab-cel® (tabelecleucel)	tudies for patients with Epstein-Barr virus associated post-transplant lymphoproliferative disease (EBV+ PTLD
AXSM	3	STRIDE-1	AXS-05 in TRD, defined as major depressive disorder which has failed to respond to two or more antidepressant treatments.
AXSM	2	AXS-05	For Smoking Cessation, data anticipated 2Q 2019	Data achieves primary endpoint.
BCRX	3	APeX-2	24-week safety and efficacy data of once-daily oral BCX7353 for prophylaxis of hereditary angioedema (HAE) attacks on-track for Q2 2019	Data failed
CARA	3	KALM-1	Top-line data in 2Q 2019	positive data
CBAY	2b	Seladepar	magnetic resonance imaging using the proton density fat fraction method (MRI-PDFF. Study for NASH.
CDTX	2	STRIVE	six poster presentations include new analyses from clinical trial of rezafungin
CNAT	2	ENCORE-LF	For Liver Function clinical trial, data expected in mid-2019	Data failed
CYTK	2	FORTITUDE-ALS	Date expected in Q2 2019	did not meet primary endpoint
FGEN	3	MACE	djudication procedures from our roxadustat Phase 3 studies for the NDA and MAA are expected to be completed in the first half of 2019	announces positive topline results
GLYC	3	GMI-1070	continued to enroll patients with sickle cell disease (SCD) in its Phase 3 clinical trial of rivipansel for the treatment of vaso-occlusive crisis (VOC) and reports that the trial remains on track to be completed in early 2019.
GWPH	3	EPIDIOLEX	trial in Tuberous Sclerosis Complex data expected Q2.
IFRX	2b	SHINE	Moderate or severe Hidradenitis Suppuratvia (HS).	fail data
IRWD	IIIb	Linaclotide	IBS-C patietns with data expected in mid-2019	Announced positive data.
MYOV	3	Relugolix	the LIBERTY 1 trial are expected in the second quarter of 2019. in women with heavy menstrual bleeding associated with uterine fibroids.	Positive data
NERV	2b	MN-101	schizophrenia, major depressive disorder and insomnia disorder Five key data readouts expected in mid-2019.
NTEC	3	ACCORDANCE	Clinical trial of AP-CD/LD global enrollment completed as of Feb 27, data may be in 2Q.
OCUL	3	OTX-TP	Data expected in first half 2019.	Data failed
SVRA	3	IMPALA study	top line results expected end of Q2 2019.	fail data
SYBX	1b/2a	SYNB1020	in patients with cirrhosis and elevated blood ammonia expected by mid-year
TCON	3	TAPPAS	trial of TRC105 in angiosarcoma interim data expected in April	Data failed
TOCA	3	Toca-5	second interim analysis expected in 2Q of 2019.	Data failed
VTGN	2	AV-101	For Major Depressive Disorder (MDD)	Data failed

Quarter 1 2019

Ticker	Phase	Drug	Notes	Data Results
ALDX	3	RASP inhibitors	Data due early Q1	success data, stock up +35.99%
ALNY	3	ENVISION	Givosiran for treatment of acute hepatic porphyria data in ealry 2019	Positive topline.
ALXN	3	ALXM210	Atypical Hemolytic Uremic Syndrome (aHUS. data expected early 2019	data success
APTX	2	NYX-2925	In subjects with painful diabetic peripheral neuropathy. Data Q1	did not meet primary endpoint
ARGX	2	argx-113	data due 1H 2019
AUPH	P2	Voclosporin	data in Jan 2019	trial did not meet primary endpoint
AXSM	3	AXS-05	resistant depression data
AXSM	2	ASCEND trial	AXS-05 MDD	Success data, +161.22%
AZN	3	LYMPARZA	data in 2019
BLPH	2a	Cohort	top-line data anticipated in 2019	Data update 1/7
CANF	2	Namodenoson	for the treatment of Liver Diseases	did not meet primary endpoint
CYTK	2	FORTITUDE-ALS	Top-line first of 2019
FCSC	2	FCX-007	for recessive dystrophic epedemolysis bullosa	Mixed data .
GILD	3	NASH and RA	Data readout in Q1	data fail
GLPG	3	FINCH1	clinical data in 2019	Positive data
ICPT	3	REGENERATE	Obeticholic acid (OCA) in nonalcoholic steatohepatitis (NASH)	Report positive data
IMGN	3	FORWARD	trial of mirvetuximab soravtansine 1h 2019	data failed
MDWD	3	NexBrid	for severe burn	endpoint met.
NVAX	2	NanoFlu Prgoram	ResVax and NanoFlu program both data expected in Q1	data updated 1/3
ONCS	2	TAVO	preliminary data
OPNT	2	OPNT001	data in Q1	did not meet primary endpoint
PIRS	2a	PRS-080	half life optimized hepcidin antagonist for anemia
PRTO	3	PATENCY-2	For treatments in patients with chronic kidney disease (CKD)	fail data
SAGE	3	SAGE217	data January	data meet endpoints, stock +42.68%
SBBP	3	LOGICS	data was scheduled for Q4 2018
SGEN	2	EV201	Top-line Data from Enfortumab Vedotin Pivotal Trial in Metastatic Urothelial Cancer Expected in the First Quarter of 2019	positive topline data
SLGL	3	SOL-GEL	Epsolay and TWIN in 2019
SNNA	3	SNA-001	Topical Phtoparticle Therapy, top-line data in late Jan or early Feb
SUPN	3	P304	Novel non stimulant for the treatment of ADHD. Data expected end of Q1 of 2019.	Mixed ADHD data
URGN	2b	UGN-102	Initial data from trial is expected in 1H 2019. In treatment with LG Non-Muscle Invasive Bladder Cancer
UROV	3	Vibegron	for Overactive bladder, data due in March 2019
VRTX	2	VX-150	Neuropathic pain	primary endpoint met.
ZFGN	2	ZGN-1061	proof-of-concept trial results ealry 2019

Quarter 4 2018

Ticker	Phase	Drug	Notes	Data Results
ACRS	2	ATI-502	data end of year	data update 12/17
ALDX	3	Reproxalap	Allergic conjunctivitis data end of quarter or 1Q '19
ALKS	3	ALKS 3831-ENLIGHTEN-2	Top-line results (fall)
AVEO	3	TIVO-3	due to slower enrollment, data is now in Q4	announced 'positive' result. Stock fall -20.08%
BHVN	2	Trigriluzole	Top-line data	achieved significance on co-primary endpoitns.
BLPH	3	INOvation-1	pulmonary arterial hypertension (PAH), with top-line data for the complete study anticipated around the end of the year
CMRX	2	CMX001	IV Brincidofovir for treatment of Viral infections
CMTA	3	MOVE trial	evaluating palovarotene. Fibrodysplasia
FOMX	3	FX 2016-11 and FX2016-12	topical minocycline foam 1.5%, for the treatment of rosace. Top-line early fourth quarter.
FOMX	3	FX2016-11 and FX2016-12	evaluating the safety and efficacy of FMX103, topical minocycline foam 1.5%, for the treatment of papulopustular rosacea. Top-line results are expected early in the fourth quarter of 2018.	report positive data
GILD	2	GS-9674	Clinical data end of year. Liver diseases
GLPG	3	FINCH 2	Topline data 2H 2018
GTHX	2a	trilaciclib	triple-negative breast cancer. trilaciclib for patients undergoing chemotherapy, are expected in the fourth quarter of 2018.	preliminary result at #SABCS18
GTXI	2	ASTRID	Top-line result expected early Q4	trial did not meet primary endpoint. 9/21
KPTI	2b	SADAL	for the treatment of patients with relapsed or refractory DLBCL
KURA	2	Tipifarnib	data from multiples phase 2 tipifarnib in solid tumor and hematologic	Stock down -18.85% after data update at #ESMO
MNLO	2	Seropitant	Data in Refractory Chronic Cough Expected in Oct 2018.	Data failed
MNLO	2	Pruritus associated with psoriasis	data in December
MRNS	2	Intravenous (IV) ganaxolone	Report top-line P2 Magnolia study in women with PPD	Data updated 12/10/18
MRNS	2	MAGNOLIA	Report top-line oral ganaxolone data from Amaryllis study in women with moderate PPD fourth quarter 2018	data updated 12/4/18
NOVN	2	SB206	Viral infections data
OBSV	3	IMPLANT 2	Clinical trial of nolasiban in IVF. Also P2a PRLONG Safety, tolerability and pharmacokinetics in pregnant women, and interim efficacy .
OPHT	2a	Zimura	In April 2018, complete patients enrollments. Evaluate data at six months.
PBYI	2	CONTROL	Top-line data	data update 12/17
PRTO	3	PATENCY-2	data Q1 '19 and possibly late '18
PULM	2a	PUR1800	for COPD
QURE	2b	AMT-061	in hemophilia B by end of year
SBBP	3	COR-003-LOGICS	Topline data
SRRA	I/II	SRA737	Interim data
SYBX	1b/2a	SYNB1020	In development for the treatment hyperammonemia. Data end of 18
SYRS	2	SY-1425	Expect to Report Initial Data from Combination Arms	Data updated, stock up 10.28% on news.
TCON	3	TRC105	interim analysis from the Phase 3 pivotal TAPPAS trial of TRC105 in angiosarcoma is expected in the second half of 2018.
UTHR	3	FREEDOM-EV	clinical data
VKTX	2	VK2809	data from P2 fatty liver and hypercholesterolemia data 2H 2018	early data on Sep 18, Stock popped +87.30%
VNDA	2	Tradipitant	for gastroparesis (gastroenterology) data end of year.	met primary endpoint, stock +25.68%
VTVT	3	STEADYFAST- Part B	data late 2018
XNCR	2	XmAb®5871	Systemic Lupus Erythematosus (SLE).

Quarter 3 2018

Ticker	Phase	Drug	Notes	Data Results
ALDX	2 and 3	Reproxalap Ocular	Phase 3 Allergic Conjunctivitis , P2b Dry Eye Disease, P3 Noninfectious Anterior Uveitis and P3 sjogren-Larsson Syndrome. All expected second half 2018	positive P2 dry eye data
ALNY	3	ENVISION	interim analysis mid-2018. Givosiran (Acute Hepatic Porphyrias)	positive data
AMRN	3	REDUCE-IT	Topline results expected to be available before the end of Q3 2018	RDUCE-IT meets primary endpoint
ANAB	2a	ANAB020	in Eosinophilic Asthma Expected in the Third Quarter of 2018	positive data
ARGS	2	AGS-004	interim data due 2h 2018
ARNA	2	Olorinab	study in pain associated with Crohn's disease	report 'positive' results
ATNX	3	Oraxol KX-ORAX-001	second inerim analysis in 3Q 2018
ATXI	3	IV tramadol	for management of moderate to moderately severe postoperative pain in patients following bunionectomy surgery.
AXON	2	Nelotanserin	REM Behavior Disorder in subject with LBD
AXSM	2	AXS-05	ASCEND study for major depressive disorder (MDD). Top-line results 2H '18
BLPH	3	PAH INOvation-1	The company continues to expect the readout of interim analyst in mid-2018.	DMC recommends stopping Phase 3.
BYSI	3	Piabulin	Interim P3 mid-2018
CANF	2	Namodenoson	Namodenoson in the treatment of heaptacellular carcinoma (HCC) expected later in 2018
CTIC	3	PIX306	trial of PIXUVRI, top-line results are expected 2Q	PIXUVRI did not meet endpoint
EIGR	2	Exendin 9-39 IN PBH	Exedin 9-39 phase 2 PREVENT study, and Ubenimex in Lymphedema; phase 2 ULTRA study completion.	Phase 2 PREVENT announce positive result
ENTX	2	PTH (1-34) and NatPar	Complete the first part of Phase 2 in Aug 1, data in coming months. Hypoparathyroidism
ESPR	3	Bempedoic Acid	Global pivotal P3 study 2 52 weeks LDL-C
FLKS	2b	COMMEND trial FLXS-787	Topline 3q 2018	Discontinue trial
FOMX	3	FX2017-22	he Company’s minocycline foam 4%, in patients with moderate-to-severe acne.	Positive late stage data
GALT	2	KEYTRUDA	enroll cohort 3 (GR-MD-02 8 mg/kg) of the pembrolizumab (KEYTRUDA) combination immunotherapy clinical trial, data mid-2018
GERN	2	IMbark	Geron expects Janssen to inform the Company of its decision by the end of the third quarter of 2018.	Discontinuation Imetelstat
GLPG	3	FINCH 2	Expect FINCH 2 results in 3Q	Data meets primary endpoint
IONS	2	AKCEA-APO(a)-LRx and AKCEA-ANGPTL3-LRx	six Phase 2 programs throughout 2018
OBSV	2B	OBE2109	due mid 2018
OMER	2	OMS721	Immunoglobulin A (IgA) nephropathy.	Mixed data result
ONCE	I/II	Hemophila A- SPK-8011	investigational gene therapy
ONCS	2b	PISCES/KEYNOTE-695	Dosing of first patient on Dec 14, 2017. data in 2018. (No specific quarter given)
OVID	2	OV101- STARS	Enrollment i n STARS trial to adolescent Angelman syndrome. Trial to be available 2H 2018	Positive data, but investors concerned stock -36.55% for the day.
PBYI	3	PB272 (neratinib)	third-line metastatic breast cancer patients in the second half of 2018
RARE	2	Crysvita (burosumab)	his is an open label Phase 2 study evaluating the safety and efficacy of burosumab in 17 adult patients with TIO.
RDHL	3	RHB-104	Topline data	Primary endpoint successfully achieved.
RYTM	2	setmelanotide	Studies of setmelanotide in BBS and Alstrom Syndrome. Sept 27-29 data.
SCYX	2b	SCY-078	Topline data by July	positive results oral SCY-078
SPPI	2	Poziotinib	Breast Cancer. Data possibly release in fall	Updated data on September 24
TGTX	3	UNITY-CLC	Top-line ORR and relapsed/refractory Chronic Lymphocytic Leukemia (CLL).	DSMB trial ORR cannot be conducted.
TNXP	3	HONOR study of Tonmya	Interim Analysis 3Q 2018;Topline results expected in 3Q 2018	discontinue Phase 3 HONOR
TORC	2b	TORC1	top-line 16 weeks data expected 3Q. trial is designed to evaluate the safety, tolerability and efficacy of RTB101, an orally-administered selective TORC1 inhibitor,	announces 'positive' P2b RTB101
URGN	3	OLYMPUS	topline data
VTL	3	VTL-308	ELAD System in subjects with severe alcoholic hepatitis (sAH). Clinical data in second half of September 2018	Data failed
ZGNX	3	ZX008	Second pivotal trial Phase 3 Dravet syndrome program, STUDY 1504. Data late June-early July.	Primary endpoint achieved

Quarter 2 2018

Ticker	Phase	Drug	Notes	Data Results
ACRS	2	AT-50002 Topical	Top-line data 1H 2018	positive interim data
ALXN	3	PREVENT and ALXN210	Data mid-2018. Eculizumab- Relapsing Neuromyelitis Optica Spectrum Disorder (NMOSD)	Success
AQXP	3	AQX-1125	LEADERSHIP data	Failed to meet primary endpoint
AXSM	3	STRIDE-1	trial of AXS-05 IN TRD, top-line data 1H 2018
BMRN	2	Hemophilia A	update on the ongoing Phase 2 program with valoctocogene roxaparvovec at the World Federation of Hemophilia 2018 World Congress. May 20-24	Data were updated at World Congress
CLDX	2b	METRIC	Topline data likely Q2 2018	Data failed
CLSD	2	TYBEE	Patients follow-up six months data	-32.19% Stock reaction to 'positive' data.
EDGE	3	EG-1962	Interim-topline data	data failed
ESPR	3	ASCVD and/or HeFH Statin add on	Global pivotal P3 study 1, 52 weeks long term safety.	Company press 'positive' data, but safety concerns dropped stock -35.11%.
FOMX	3	FMX103	Topline data mid 2018
GBT	3	HOPE study	Top -line clinical data by end of quarter	Primary endpoint achieved
GEMP	2B	INDIGO-1	Top-line data	Meet primary endpoint
GLMD	2b	ARREST	Phase IIB data late Q1 or early Q2 2018.	Data update stock up +151.29%
GNMX	2	AEVI-001	Phase 2 (ASCEND) for patients with ADHD. Data expected mid-2018
HRTX	2	HTX-011	data likely late Q2 for kneee arthroplasty	positive topline results. Stock up +30.13%
IDRA	2	IMO-8400	Topline data in June	miss primary endpoint
INCY	3	ECHO-301	Initial results of the ECHO-301 trial of epacadostat in melanoma and REACH 1 trial of ruxolittinib in acute GVHD	Data failed
IONS	P1/2a	IONIS-SOD1 ALS	Topline Data Mid Q2
JNCE	1/2	ICONIC	Preliminary Efficacy data in the first half of 2018	Underwhelming abstract, stock -35.20% reaction
KPTI	2	STORM	April data	Positive Phase 2a
MDGL	2	MGL-3196	Final 36-week data, top line results by end of May	MDGL-3196 Achieves Endpoints
MNLO	2	ATOMIK	atopic dermatitis data expected April 2018	Data failed
NBRV	3	LEAP 2	Data are expecting in Spring 2018	Company press lefamulin meets all primary endpoints. Stock down -16.57%
PRTA	IIb	NEOD1	Top-line data	Data failed, stock down -68.78%
SBBP	3	RECORLEV	Top-line results on track with SONICS	Positive results.
SELB	2	SEL-212	Symtomatic Gout Patients. Updated Clinical data at PANLAR Congress on Tuesday, April 10, 2018
VICL	2	HSV-2	Therapeutic Vaccine	trial vaccine did not meet primary endpoint
VTVT	3	STEADFAST	STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018	Data failed
XLRN	3	MEDALIST and BELIEVE	Data mid 2018	Achieved primary and secondary endpoints

Quarter 1 2018

Ticker	Phase	Drug	Notes	Data Results
ACOR	3	Tozadenant	Phase 3 data
AIMT	3	PALISADE	"Anticipate sharing topline in first quarter 2018"
ANTH	3	Sollpura-RESULT	data due end of Q1
ARGX	2	ARGX-113	Myasthenia gravis data
AXON	2	Intepirdine and Nelotanserin	January data: HEADWAY in patients with dementia with Levy bodies (DLB). subjects with Alzheimer's disease, DLB and Parkinson's disease dementia (PDD). Nelotanserin (LBD).
AXSM	3	CREATE-1	trial of AXS-02 in CRPS, interim efficacy analysis
BLPH	3	INO pulse for PAH indication	Topline line data
BOLD	1/2	AT132	Phase 1/2 data readout of AT132 XLMTM
CDTX	2	STRIVE	CD101 IV
Cidara Therapeutics Inc (CDTX)	2	STRIVE	completing enrollment of the 90-patietn. P2 Rezafungin
CLSD	3	PEACHTREE	Macular Edema Associated with Non-infectious Uveitis, top line data.
CPRX	2	CMS-001	Expect top-line results from CMS-001 in first half 2018
DERM	3	CLAREOS 1 and CLAREOS 2	October 5, 2017 completes patient enrollment in Two Phase 3 pivotal trials of Olumacostat Glasaretil for the treament of Acne Vulgaris. Topline.
EARS	3	KEYZILEN	P3 TACTT3 topline data
EIGR	2	LIBERTY	Ubenimex in PAH
EYEG	3	EGP-437	Topline data
FGEN	2	FG-3019	Pancreatic caner study results
FLKS	2	FLX-787 Multiples Sclerosis	Readout data end of Q1
GEMP	2b	INDIGO-1	top-line data
GTHX	2a	trilaciclib	trilaciclib first-in-line small cell lung cancer. Data in March
IDRA	2	IMO-2125	Clinical trial of 8mg intratumoral IMO-2125 in combination with ipilimumab in anti-PD1 reffractory melanoma. ORR data
MNOV	2	mn-166	Completion enrollment news on Sept 19,2017. Final data Q1
MRNS	2	CDKL5	on-going in the Magnolia Study, with data expected in early 2018
OVID	2	STARS	Sometimes 2018
PTGX	2b	PTG-300	interim analysis early 2018
REGN	3	Praluent ODYSSEY OUTCOMES	Cardiovascular events.
TCON	2	TRAXAR trial of TRC105	Top-line data from the randomized P2
TRPX	IIa	THX-110	Tourette syndrome. Top-line anticipated in first half 2018
TTPH	3	IGNITE3	Additional data
VBLT	3	VB-111	top-line results
VICL	3	ASP0013	The multinational phase 3 registration trial in HCT recipients completed enrollment in Sept 2016 with a total 515 subjects.
VRTX	2	VX-445 and VX-659 triple combinations in CF patietns	data 1H18
VTGN	2	AV-101	P2 monotherapy study completion expected early 2018
VTVT	3	STEADFAST	STEADFAST study (azeliragon in Alzheimer's disease) Part A early 2018	Data failed

Quarter 4 2017

Ticker	Phase	Drug	Notes	Data Results
ADRO	2	CRS-207 in combination with pembrolizumab	Report early observations from the ongoing phase 2 mesothelioma study
AGLE	1	AEB1102	Potential data end of year.
ARDX	3	T3MPO-2	Results of Tenapanor for IIBS-C on track early Q4
AVXL	2a	ANAVEX 2-73	PK/PD data
CALA	2	CB-839	In July 2017, Calithera initiated a phase 2 trial of CB-839 with pcitaxel in triple negative breast cancer patietns.
CLDX	2	Glembatumumab Vedotin	The company anticipated in fall of 2017
CNCE	2b	CTP-543	End of year data
CPRX	3	Firdapse®	Top-line Results expected in early December. Completes enrollment in second phase 3 trial on Oct 31,2017
DBVT	3	PEPITES	to report topline results from PEPITES in October 2017
EARS	3	AM-111 HEALOS	The trial enrolled 256 patients with severe to profound idiopathic sudden sensorineural hearing loss.
EIGR	2	LIMT HDV	interim data study at AASLD
GALT	2b	NASH-CX	Clinical data in December
IRWD	2	IW-1973	data from two phase IIa studies with IW-1973 in diabetic patients with hypertension are expected by end of 2017.
KDMN	2	KD025	Randomized, open-label clinical trial in idiopathic pulmonary fibrosis
KDMN	2	KD025	Randomized, open-label clinical trial in idiopathic pulmonary fibrosis and full data to severe psoriasis
KURA	2	tipifarnib	Phase 2 trial of tipifarnib in HRAS mutant SCCHN second half 2017
MDGL	2	MGL-3196 for NASH	Top-line results for the primary endpoint of the trial, the reduction of liver fat, assessed by MRI-PDFF at 12 weeks, are expected by year-end
MLNT	2/3	Taksta	exploratory trial data in refractory bone and joint infections.
MNOV	2b	SPRINT-MS/NN 102	phase 2b Trial of Ibudilast in progressive MS has been accepted for oral platform presentation at 7th Join ECTRIMS*ACTRIMS meeting October 25-28, 2017 in Paris, France
ONTX	3	INSPIRE	interim analysis anticipate in Q4
RARX	2	RA101495	Cohort B of Ra Pharma's Phase 2. The company remains on track to report additional data around year-end.
RVNC	2	RT002	RT002 injectable in management of plantar fascitis
RVNC	3	SAKURA 1&2	rt002 Injectable for the treatment of glabellar (frown) lines
SAGE	2	SAGE-217	SAGE-217 in PPD and essential tumor 2H2017
SGEN	3	ADCETRIS	Full data from ADCETRIS phase 3 ECHELON-1 trial
STML	2	SL-401	In Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Top line results in 2h17
SYRS	2	SY-1425	on track to present initial phase 2 clinical data
TGTX	2	TG-1101	multiples sclerosis trial update
VKTX	2	VK5211	Phase 2 hip fractured study full enrolled, data expected Q4 '17. From Aug 19 press released

Quarter 3 2017

Ticker	Phase	Drug	Notes	Data Results
ABBV	3	SELECT-BEYOND	top-line data likely 3Q
ABUS	2	HBV	ARB1467 data
ABUS	2	ARB-1467	top-line results from the three-month bi-weekly dosing expect to be announced in September
ALDX	2A	ADX-102	Clinical trial in Dry Eye Disease
ALNY	2	hempohillia	Fitusiran PII OLE dadta
ALNY	3	APOLLO	results for Patisiran in near term
ANTH	2	BRIGHT	BRIGHT study of blisibimod in IgA
ARRY	3	BEACON CRC	data from the safety due at ESMO
AXON	3	Alzheimer's disease	Data to be out in September 2017
AZRX	IIa	MS1819	expect completion Phase IIa in 3Q
BLPH	2a	PH-IPF	"results of this study in near futture" -Mr. Tenenbaum
FOLD	3	SD-101	SD-101 for Epidermolysis Bullosa (EB), Top-line P3 late 3Q
GILD	2	GS-0976	NASH data
GTXI	2	Enobosarm	top-line results in 3Q
INSM	3	ARIKAYCE	data out in September
KDMN	2	KD025	Open-label, dose finding clinical trial in chronic graft-versus-host disease. Also Tesevatinib data
MDCO	3	Meropenem-Vaborbactam	TANGO 2 end of 3Q
MRNS	2	CDKL5	Phase 2 trial evaluating children with CDKL5 disorder
MRTX	2	NSCLL	AMETHYST trial
NBRV	3	Infections	LEAP 1 data.
OTIC	3	AVERTS-1	Phase 3 AVERTS-1 trial for OTIVDEX(tm) in September
RDHL	2	BEKINDA	IBS-D data in September
SAGE	3	Brexanolone in SRSE	top-line results from STATUS trial
STML	2	SL-401	top-line results in 2h17
VNDA	2	Tradipitant	study for treatment of chronic pruritus in patients with atopic dermatitis.
VSAR	3	Pediatric GHD	Top line from pediatric phase 3 Velocity trial around end of September
VSTM	3	Duvelisib	Phase 3 DUO top-line latter part of summer
ZYNE	2	FAB-C	top-line results from the FAB-C Fragile X study in September

Quarter 4 20018

Ticker	Phase	Drug	Notes	Data Results
FGEN	3	Roxadustat	topline data for anemia in chronic kidney disease